Longevous founders Robert Mohr and Avi Roy, along with their team, will join Temple full time, Goyal said in a post on X.

Mohr will join the startup as its chief medical officer. He has nearly two decades of clinical experience and has worked across emergency medicine, preventive medicine, and precision medicine. At Temple, he will oversee the clinical rigour of the startup's experiments and health-related claims.

Meanwhile, Roy will take over as Temple's head of science. An Oxford-trained biomedical scientist, Roy previously cofounded Founders Health and UDA and worked as a research fellow at the University of Oxford's Centre for the Advancement of Sustainable Medical Innovation.

Founded in 2025, Longevous focuses on preventive and precision medicine, helping clients use science-backed therapies and health data to improve their long-term health and lifespan.

In his post, Goyal said the two founders had also been working with Temple's science team over the past few months to test its 'Entropy' metric, assess data collected through its wearable and review the startup's first scientific manuscripts ahead of submission.

Longevous will continue operating as before as part of Temple, with Mohr and Roy continuing to look after its clients, he added.

Temple's Wearable Nears Launch

The acquisition comes days after Goyal unveiled the latest design of Temple's wearable, saying it is now less than half the size of the earlier version. He also said pre-orders for a limited-edition version will open soon, with shipments expected by the end of 2026.

Goyal had earlier said Temple had shipped its first cohort of 100 devices. The startup has partnered with contract manufacturers Zetwerk and Ethereal Machines to scale production, while planning to keep primary manufacturing in-house.

The wearable is being developed around Goyal's biological research initiative, Continue Research, and its first hypothesis, dubbed "Gravity Ageing". The hypothesis examines whether gravity's lifelong effect on blood circulation to the brain, or cerebral blood flow (CBF), could contribute to age-related decline in certain brain functions.

According to the hypothesis, gravity pulls blood away from the brain when people stand or sit, potentially reducing CBF by up to 17% in an upright posture. Temple's wearable is expected to measure cerebral blood flow and could provide users with data linked to brain health.

However, Goyal has indicated that the device will function as a standalone consumer product even if the Gravity Ageing hypothesis does not hold up.

In February, Temple raised $54 Mn in seed funding from investors including Steadview Capital, Peak XV Partners, Vy Capital and Info Edge Ventures.

The startup reportedly also began offering liquidity to employees through an employee stock ownership plan (ESOP) buyback that values Temple at $375 Mn, nearly double its valuation at the time of its seed round.

Temple is among a growing group of healthtech startups exploring new applications and form factors for wearable devices.

While traditional smartwatches remain popular for fitness and health tracking, startups are increasingly exploring alternatives such as smart rings and specialised devices. Temple's focus on cerebral blood flow marks another attempt to expand wearables beyond conventional fitness tracking into areas such as preventive health, longevity and brain health.

Startups such as Ultrahuman, Gabit, Noise, FITTR, Sychedelic, and Sophrosyne are exploring smart rings, EEG-based headphones and biosensing solutions to tap the growing wearable market, which is expected to reach $4.4 Bn by 2034, growing at a 14.9% CAGR.